MOLN: 11% | Molecular Partners shares are trading higher after the company announced the debut of their lead Raido-DARPin therapy candidate MP0712, targeting DLL3.
OSG: 63% | QuantaSing Group Limited Announced Up To US$20M Share Repurchase Program
CMND: 29% | Clearmind Medicine shares are trading higher after the company announced advancement in its proprietary MEAI-based alcohol substitute beverage program.